



CLAU

21shares Anthropic
Synthetic ETP

Factsheet as of 12 October,
2026¹

INVESTMENT OBJECTIVE

Anthropic, the artificial intelligence research company best known for creating Claude and Claude Code, has attracted significant investor attention ahead of an anticipated public listing.

21shares Anthropic Synthetic ETP is an exchange-traded product (ETP) that provides investors with exposure to Anthropic's current market-implied valuation, before the company completes its initial public offering (IPO). The ticker symbol for this product is CLAU.

CLAU provides synthetic exposure, not direct equity ownership. The product gains its exposure via notes issued by FalconX Group, 21shares' parent company, which acts as the note counterparty and manages exposure through perpetual futures contracts.

PRODUCT DETAILS

Issuer	21shares x FalconX Limited
Fee	1.00%
ISIN	CH1606386675
Listing Date	08.10.2026
UCITS Eligible	Yes ²
AIF Eligible	Yes ³
871(m)	Not applicable ⁴
Sharia Compliance	No
Replication Method	Synthetic
Domicile	Cayman Island
Lending Eligible	No
Base Prospectus	
AT, BE, BG, CY, CZ, DE, DK, EE, ES, FI, FR, GR, HR, HU, IE, IT, LI, LT, LU, LV, MT, NL, NO, PL, PT, RO, SE, SK	

KEY FACTS

AUM	\$49,397.23
Securities Outstanding	5,000
Nav Per Unit	\$9.88
30 Days Change	+0.00%

SERVICE PROVIDERS

Market Maker

Virtu Financial Ireland Limited

Custody

Bank Frick

Authorized Participants

Virtu Financial Ireland

Collateral Agent

The Law Debenture Trust Corporation PLC

¹Updated monthly ²This varies by jurisdiction and the fund manager is recommended to verify this ³Under the condition that the AIF units are only marketed to well-informed investors, as communicated by the CSSF This varies by jurisdiction and the fund manager is recommended to verify this. ⁴Subject to change



BENEFITS

Why invest

For many investors, gaining direct exposure to high profile privately held companies is not possible, since they can be exclusive to investors who meet eligibility criteria that only institutional investors or private equity funds typically satisfy.

21shares has now provided a solution to this via the pre-IPO perpetuals market which gives exposure to the valuation of a private company. Some investors view this period before a high-profile IPO as a meaningful window for building exposure before public markets set the entry price.

It is important to be aware that the gap between a company's pre-IPO implied valuation and its eventual post-IPO valuation can be significant in either direction. As a result, investors should be prepared for the possibility that the price of the 21shares Anthropic Synthetic ETP can go up as well as down.

Why access Anthropic through an ETP?

For investors who have decided they want exposure to Anthropic's market-implied valuation before any eventual IPO, the ETP structure solves the two main access barriers.

First, gaining direct exposure to pre-IPO companies requires participation in private funding rounds or secondary market transactions on specialist platforms. These routes are typically restricted to institutional investors, venture funds, or individuals meeting platform-specific eligibility criteria. Minimum transaction sizes are generally significant.

Second, private equity holdings may face lock-up periods that restrict sale of their position around the time of the IPO.

Exchange-listed products are not subject to these same constraints. The 21shares Anthropic Synthetic ETP can be bought or sold through your investing account, and there is no eligibility criteria beyond those of the investor's existing brokerage arrangement.

Investors should understand that the product provides synthetic price exposure through a derivative structure via a note issued by FalconX Group, not direct equity ownership. It does not confer voting rights or other shareholder privileges in Anthropic and may not be comparable to private holdings of a reference entity.

Continuity of exposure through the IPO

The ETP is structured to continue trading without interruption through Anthropic's IPO. When Anthropic receives a public listing, the reference price used by the product's perpetual futures positions transitions from private market valuations and secondary transaction data to Anthropic's official exchange-quoted spot price. There is no forced settlement and no requirement to convert to physical equity.

Investors should note that the product does not convert to Anthropic shares at IPO. It continues to hold synthetic exposure through FalconX Group-issued notes backed by perpetual futures. The NAV will reflect Anthropic's public spot price, adjusted for the 1% annual product fee and ongoing variable funding rate costs.

To learn more, read this article URL: <https://www.21shares.com/insights/pre-ipo-etp>

TRADING INFORMATION

Bloomberg	RIC	WKN	Valor
CLAU SW	CLAU.S	A4AWPL	160638667

EXCHANGES, LOCAL TICKER AND CURRENCY

Exchange	Local Ticker	Currency
Vienna MTF	CLAU AV	EUR

FUNDAMENTALS

- Anthropic PBC is an artificial intelligence research company best known for creating Claude and Claude Code. It has attracted significant investor attention ahead of an anticipated public listing ("IPO").
- For investors seeking exposure to Anthropic's pre-IPO valuation, CLAU solves the main access barriers of traditional finance: gaining direct exposure traditionally requires participation in private funding rounds or secondary market platforms. Private equity holdings also usually face lock-up periods that restrict sales around an IPO. On contrary, CLAU provides easy access to the implied pre-IPO valuation through perpetual futures of Anthropic PBC.
- As the first ETP tracking the Implied Reference Entity value of Anthropic PBC, CLAU is a highly innovative product available to European investors through traditional brokers and investment platforms.

RISK FACTORS

- Anthropic PBC perpetual futures are novel instruments. For example, Binance opened trading for ANTHROPICUSDT perpetual futures in June 2026.
- There is no guarantee that Anthropic PBC will IPO. Furthermore, the ETP does not convert to Anthropic shares at the event of an IPO, and there is no forced settlement. If Anthropic goes through a public listing, the reference price will take into account Anthropic's official exchange-quoted price.
- As CLAU obtains synthetic exposure to the Implied Reference Entity Value, the performance of the ETP may not precisely replicate the performance of the relevant Reference Asset ("IREV Asset" with Reference Entity: Anthropic PBC). Such tracking differences may be positive or negative and may vary over time. Moreover, the ETP does not confer voting rights or other shareholder privileges in Anthropic PBC.
- The ETP gains the synthetic exposure via notes issued by FalconX Group, 21shares' parent company. As such, the product carries counterparty risk on FalconX Group-issued notes.

ABOUT US

Crypto Made Easy

21shares offers the world's largest suite of cryptocurrency exchange-traded products (ETPs) with the mission to enhance accessibility to crypto investing. The company pioneered the world's first physically backed ETP in 2018 and consistently expands its offerings with cutting-edge products backed by comprehensive research. Catering to both institutional and retail investors, 21shares combines traditional finance (TradFi) and decentralized finance (DeFi) expertise. Based in Zurich, London and New York, the team consists of skilled entrepreneurs, engineers, researchers, and financial experts committed to transforming cryptocurrency investment.

CONTACT US

21shares.com

Sales: sales@21shares.com | Capital Markets: capital.markets@21shares.com | Research: research@21shares.com

21shares.com

Sales: sales@21shares.com | Capital Markets: capital.markets@21shares.com | Research: research@21shares.com

21shares

DISCLAIMER

Past performance is not a reliable indicator of future results and should not be a sole factor of consideration when selecting a product. This document is not an offer to sell or a solicitation of an offer to buy or subscribe for securities of 21Shares x FalconX Limited in any jurisdiction. Neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever or for any other purpose in any jurisdiction. Nothing in this document should be considered investment advice.

For investors in the USA, Canada or Australia: This document and the information contained herein are not for distribution in or into (directly or indirectly) the United States, Canada, Australia or Japan or any other jurisdiction in which the distribution or release would be unlawful. This document does not constitute an offer of securities for sale in or into the United States, Canada, Australia or Japan. The securities of 21Shares x FalconX Limited to which these materials relate have not been and will not be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold

in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There will not be a public offering of securities in the United States. Neither the US Securities and Exchange Commission nor any securities regulatory authority of any state or other jurisdiction of the United States has approved or disapproved of an investment in the securities or passed on the accuracy or adequacy of the contents of this presentation. Any representation to the contrary is a criminal offence in the United States.

For investors in Switzerland and United Kingdom: This document does not constitute a promotion of securities for sale in or into Switzerland or in the United Kingdom. There will not be a public offering of securities in Switzerland or in the United Kingdom. This advertisement is only available to professional investors in those jurisdictions.

Exclusively for potential investors in any EEA Member State that has implemented the Prospectus Regulation (EU) 2017/1129 the Issuer's Base Prospectus (EU) is made available on the Issuer's website under <https://www.21shares.com/en-eu/product-documents/prospectus?subcategory=21shares-x-falconx>. The approval of the Issuer's Base Prospectus (EU) should not be understood as an endorsement by the SFSA of the securities offered or admitted to trading on a regulated market. Eligible potential investors should read the Issuer's Base Prospectus (EU) and the relevant Final Terms before making an investment decision in order to understand the potential risks associated with the decision to invest in the securities. You are about to purchase a product that is not simple and may be difficult to understand.

This document constitutes advertisement within the meaning of the Prospectus Regulation (EU) 2017/1129 and not a prospectus. The 2026 Base Prospectus of 21Shares x FalconX Limited and the key information document for any products may be obtained at 21Shares x FalconX Limited website (<https://www.21shares.com/en-eu/product-documents/prospectus?subcategory=21shares-x-falconx> or <https://21shares.com/ir/kids>).